JP2003520823A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003520823A5 JP2003520823A5 JP2001554698A JP2001554698A JP2003520823A5 JP 2003520823 A5 JP2003520823 A5 JP 2003520823A5 JP 2001554698 A JP2001554698 A JP 2001554698A JP 2001554698 A JP2001554698 A JP 2001554698A JP 2003520823 A5 JP2003520823 A5 JP 2003520823A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- fsh
- days
- follicular
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003325 follicular Effects 0.000 description 30
- 230000000638 stimulation Effects 0.000 description 27
- 238000011282 treatment Methods 0.000 description 22
- 210000000287 oocyte Anatomy 0.000 description 17
- 230000002611 ovarian Effects 0.000 description 16
- 102000006771 Gonadotropins Human genes 0.000 description 15
- 108010086677 Gonadotropins Proteins 0.000 description 15
- 239000002622 gonadotropin Substances 0.000 description 15
- 238000002347 injection Methods 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- 230000016087 ovulation Effects 0.000 description 15
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 238000013459 approach Methods 0.000 description 10
- 238000002604 ultrasonography Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 9
- 230000035935 pregnancy Effects 0.000 description 9
- 102000009151 Luteinizing Hormone Human genes 0.000 description 8
- 108010073521 Luteinizing Hormone Proteins 0.000 description 8
- 229960005309 estradiol Drugs 0.000 description 8
- 229930182833 estradiol Natural products 0.000 description 8
- 229940040129 luteinizing hormone Drugs 0.000 description 8
- 230000004720 fertilization Effects 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 6
- 230000035800 maturation Effects 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 5
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 5
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 5
- 208000021267 infertility disease Diseases 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 208000034702 Multiple pregnancies Diseases 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 239000003708 ampul Substances 0.000 description 4
- 230000035558 fertility Effects 0.000 description 4
- 229940094892 gonadotropins Drugs 0.000 description 4
- 208000000509 infertility Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000011599 ovarian follicle development Effects 0.000 description 4
- 230000001850 reproductive effect Effects 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 108010020661 Profasi Proteins 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 230000008217 follicular development Effects 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 231100000535 infertility Toxicity 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 description 2
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 238000003744 In vitro fertilisation Methods 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000000624 ovulatory effect Effects 0.000 description 2
- 210000004508 polar body Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000009612 semen analysis Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010042573 Superovulation Diseases 0.000 description 1
- 241000656145 Thyrsites atun Species 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002513 anti-ovulatory effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003826 endocrine responses Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000036266 weeks of gestation Effects 0.000 description 1
- 108010055450 with HCG C-terminal peptide human follicle stimulating hormone Proteins 0.000 description 1
- 210000004340 zona pellucida Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00300591 | 2000-01-27 | ||
| EP00300591.5 | 2000-01-27 | ||
| EP00302840A EP1142582A1 (en) | 2000-04-04 | 2000-04-04 | Use of FSH for treating infertility |
| EP00302840.4 | 2000-04-04 | ||
| PCT/GB2001/000065 WO2001054715A1 (en) | 2000-01-27 | 2001-01-09 | Use of fsh for treating infertility |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003520823A JP2003520823A (ja) | 2003-07-08 |
| JP2003520823A5 true JP2003520823A5 (enExample) | 2011-04-21 |
| JP5170928B2 JP5170928B2 (ja) | 2013-03-27 |
Family
ID=26072975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001554698A Expired - Lifetime JP5170928B2 (ja) | 2000-01-27 | 2001-01-09 | 不妊症の治療のためのｆｓｈの使用 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US7291593B2 (enExample) |
| EP (2) | EP1442748A1 (enExample) |
| JP (1) | JP5170928B2 (enExample) |
| KR (2) | KR100871499B1 (enExample) |
| CN (1) | CN1418107A (enExample) |
| AR (1) | AR027287A1 (enExample) |
| AT (1) | ATE267608T1 (enExample) |
| AU (1) | AU783121B2 (enExample) |
| BG (1) | BG65915B1 (enExample) |
| BR (1) | BR0107881A (enExample) |
| CA (1) | CA2397680A1 (enExample) |
| CZ (1) | CZ302835B6 (enExample) |
| DE (1) | DE60103503T3 (enExample) |
| DK (1) | DK1250148T4 (enExample) |
| EA (1) | EA004924B1 (enExample) |
| EE (1) | EE05444B1 (enExample) |
| ES (1) | ES2217113T5 (enExample) |
| HR (1) | HRP20020630A2 (enExample) |
| HU (1) | HU230833B1 (enExample) |
| IL (2) | IL150837A0 (enExample) |
| MX (1) | MXPA02007233A (enExample) |
| NO (1) | NO324626B1 (enExample) |
| PL (1) | PL211113B1 (enExample) |
| PT (1) | PT1250148E (enExample) |
| RS (1) | RS50805B (enExample) |
| SI (1) | SI1250148T2 (enExample) |
| SK (1) | SK287717B6 (enExample) |
| TR (1) | TR200401810T4 (enExample) |
| WO (1) | WO2001054715A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002324183B2 (en) * | 2001-09-12 | 2007-10-25 | Merck Serono Sa | Use of hCG and LH in controlled ovarian hyperstimulation |
| DE60238490D1 (de) | 2001-09-12 | 2011-01-13 | Merck Serono Sa | Verwendung von humanem choriongonadotropin (hcg) und luteinisierendem hormon (lh) zur regulierten hyperstimulation der eierstöcke |
| CA2457849A1 (en) | 2001-09-12 | 2003-03-20 | Applied Research Systems Ars Holding N.V. | Use of hcg in controlled ovarian hyperstimulation |
| UA88879C2 (en) * | 2003-09-02 | 2009-12-10 | Эплайд Рисерч Системз Эрс Холдинг Н.В. | Fsh glycosylation mutant |
| US7481748B2 (en) * | 2005-09-22 | 2009-01-27 | Kurt Manufacturing Company, Inc. | Locking mechanism for a bicycle trainer |
| WO2008140794A1 (en) * | 2007-05-11 | 2008-11-20 | The Texas A & M University System | Hormone normalization therapy and uses thereof |
| AR081755A1 (es) * | 2010-04-02 | 2012-10-17 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo |
| CA2934579A1 (en) * | 2013-12-20 | 2015-06-25 | Fertilify Inc. | Compositions comprising vitamin c, vitamin e, and coenzyme q10 and use thereof for promoting female fertility and reproductive health |
| EP4427806A3 (en) * | 2017-09-01 | 2024-10-09 | Ferring B.V. | Composition for controlled ovarian stimulation |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4725579A (en) * | 1985-02-21 | 1988-02-16 | Serono Laboratories, Inc. | Method of in vitro fertilization by a unique combination of gonadotropins |
-
2001
- 2001-01-09 EA EA200200801A patent/EA004924B1/ru not_active IP Right Cessation
- 2001-01-09 WO PCT/GB2001/000065 patent/WO2001054715A1/en not_active Ceased
- 2001-01-09 TR TR2004/01810T patent/TR200401810T4/xx unknown
- 2001-01-09 AU AU25321/01A patent/AU783121B2/en not_active Expired
- 2001-01-09 US US10/182,138 patent/US7291593B2/en not_active Expired - Lifetime
- 2001-01-09 EP EP04006375A patent/EP1442748A1/en not_active Withdrawn
- 2001-01-09 HR HRP20020630 patent/HRP20020630A2/hr not_active Application Discontinuation
- 2001-01-09 AT AT01900491T patent/ATE267608T1/de active
- 2001-01-09 MX MXPA02007233A patent/MXPA02007233A/es active IP Right Grant
- 2001-01-09 CN CN01806573A patent/CN1418107A/zh active Pending
- 2001-01-09 HU HU0204324A patent/HU230833B1/hu unknown
- 2001-01-09 PL PL356925A patent/PL211113B1/pl unknown
- 2001-01-09 BR BR0107881-0A patent/BR0107881A/pt not_active Application Discontinuation
- 2001-01-09 JP JP2001554698A patent/JP5170928B2/ja not_active Expired - Lifetime
- 2001-01-09 ES ES01900491T patent/ES2217113T5/es not_active Expired - Lifetime
- 2001-01-09 KR KR1020077017998A patent/KR100871499B1/ko not_active Expired - Lifetime
- 2001-01-09 EE EEP200200415A patent/EE05444B1/xx unknown
- 2001-01-09 CZ CZ20022555A patent/CZ302835B6/cs not_active IP Right Cessation
- 2001-01-09 CA CA002397680A patent/CA2397680A1/en not_active Abandoned
- 2001-01-09 SK SK1096-2002A patent/SK287717B6/sk not_active IP Right Cessation
- 2001-01-09 IL IL15083701A patent/IL150837A0/xx unknown
- 2001-01-09 EP EP01900491A patent/EP1250148B2/en not_active Expired - Lifetime
- 2001-01-09 PT PT01900491T patent/PT1250148E/pt unknown
- 2001-01-09 SI SI200130111T patent/SI1250148T2/sl unknown
- 2001-01-09 DE DE60103503T patent/DE60103503T3/de not_active Expired - Lifetime
- 2001-01-09 KR KR1020027009518A patent/KR100871502B1/ko not_active Expired - Lifetime
- 2001-01-09 DK DK01900491T patent/DK1250148T4/da active
- 2001-01-09 RS YUP-567/02A patent/RS50805B/sr unknown
- 2001-01-25 AR ARP010100325A patent/AR027287A1/es unknown
-
2002
- 2002-07-11 NO NO20023354A patent/NO324626B1/no not_active IP Right Cessation
- 2002-07-22 IL IL150837A patent/IL150837A/en active IP Right Grant
- 2002-07-23 BG BG106943A patent/BG65915B1/bg unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ichael Ludwig et al. | Use of recombinant human chorionic gonadotropin in ovulation induction | |
| RS56702B1 (sr) | Anti-fap antitela i metode primene | |
| JP4616999B2 (ja) | プログラム管理された卵巣刺激プロトコルのための方法 | |
| JP2003520823A5 (enExample) | ||
| EP1250148B1 (en) | Use of fsh for treating infertility | |
| AU2003274929B2 (en) | Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method | |
| Adel | GnRH agonis short protocol versus GnRH antagonist flexible protocols in poor responder undergoing in vitro fertilization treatment. | |
| AU2005203211B2 (en) | Use of FSH for treating infertility | |
| Kumar et al. | Effect of Oral Contraceptive Pill Pretreatment on Pregnancy Rates in Patients Stimulated with GnRH Antagonists and rFSH for ICSI | |
| EP1142582A1 (en) | Use of FSH for treating infertility | |
| Al Krayem et al. | Mild stimulation versus conventional ovarian stimulation in a cohort of poor responders. | |
| CN116490202A (zh) | 用于治疗多囊卵巢综合征患者的不孕症的hp-hmg | |
| Kahyaoğlu et al. | A Successful Pregnancy by Utilization of Gradually Increasing Low Dose Gonadotrophin Stimulation in a Modified Natural Cycle in Vitro Fertilization Procedure: Case Report | |
| HK1053426A (en) | Use of fsh for treating infertility | |
| Chou et al. | Outcomes of high initial daily doses of gonadotropin in patients with poor ovarian reserve | |
| Sohn et al. | Management of the non-responsive | |
| Ali et al. | Pregnancy in high FSH: a new modality of treatment |